I-Mab ADR (IMAB): Price and Financial Metrics

I-Mab ADR (IMAB): $3.35

-0.25 (-6.94%)

POWR Rating

Component Grades














  • Growth is the dimension where IMAB ranks best; there it ranks ahead of 91.72% of US stocks.
  • The strongest trend for IMAB is in Growth, which has been heading down over the past 179 days.
  • IMAB's current lowest rank is in the Quality metric (where it is better than 3.58% of US stocks).

IMAB Stock Summary

  • IMAB's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.43 -- higher than merely 4.95% of US-listed equities with positive expected earnings growth.
  • Over the past twelve months, IMAB has reported earnings growth of 14,959.68%, putting it ahead of 99.8% of US stocks in our set.
  • Revenue growth over the past 12 months for I-MAB comes in at -92.84%, a number that bests only 1.15% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to I-MAB, a group of peers worth examining would be ERIC, LI, LPCN, VERU, and PACB.
  • Visit IMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.i-mabbiopharma.com.

IMAB Stock Price Chart Interactive Chart >

Price chart for IMAB

IMAB Price/Volume Stats

Current price $3.35 52-week high $21.44
Prev. close $3.60 52-week low $3.19
Day low $3.33 Volume 286,800
Day high $3.67 Avg. volume 496,098
50-day MA $5.02 Dividend yield N/A
200-day MA $5.96 Market Cap 278.38M

I-Mab ADR (IMAB) Company Bio

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

IMAB Latest News Stream

Event/Time News Detail
Loading, please wait...

IMAB Latest Social Stream

Loading social stream, please wait...

View Full IMAB Social Stream

Latest IMAB News From Around the Web

Below are the latest news stories about I-MAB that investors may wish to consider to help them evaluate IMAB as an investment opportunity.

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.

Yahoo | March 20, 2023

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. . During today’s call, we will be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, […]

Yahoo | March 10, 2023

Q4 2022 TRACON Pharmaceuticals Inc Earnings Call

Q4 2022 TRACON Pharmaceuticals Inc Earnings Call

Yahoo | March 9, 2023

MSCI ESG Updated I-Mab to "A" Rating

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan Stanley Capital International) ESG, following MSCIESG's most recent annual review, and such rating outperforms 66% peers among global biotech companies.

Yahoo | March 7, 2023

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 25, 2023

Read More 'IMAB' Stories Here

IMAB Price Returns

1-mo -24.21%
3-mo -3.74%
6-mo -27.02%
1-year -82.85%
3-year -70.22%
5-year N/A
YTD -19.86%
2022 -91.18%
2021 0.51%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7855 seconds.